Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, Boucher L, Gupta NT, Gupta S, Adler C, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Thurston G, Ambati SR, Jankovic V.
Brouwer-Visser J, et al. Among authors: ambati sr.
J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338.
J Immunother Cancer. 2024.
PMID: 38519055
Free PMC article.